HomeCompareORPHY vs ADC

ORPHY vs ADC: Dividend Comparison 2026

ORPHY yields 6666.67% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORPHY wins by $1028095347812061.75M in total portfolio value
10 years
ORPHY
ORPHY
● Live price
6666.67%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1028095347812062.00M
Annual income
$998,628,545,336,266,700,000.00
Full ORPHY calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — ORPHY vs ADC

📍 ORPHY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORPHYADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORPHY + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORPHY pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORPHY
Annual income on $10K today (after 15% tax)
$566,666.67/yr
After 10yr DRIP, annual income (after tax)
$848,834,263,535,826,600,000.00/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ORPHY beats the other by $848,834,263,535,826,500,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORPHY + ADC for your $10,000?

ORPHY: 50%ADC: 50%
100% ADC50/50100% ORPHY
Portfolio after 10yr
$514047673906031.06M
Annual income
$499,314,272,668,133,400,000.00/yr
Blended yield
97.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

ORPHY
No analyst data
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORPHY buys
0
ADC buys
0
No recent congressional trades found for ORPHY or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORPHYADC
Forward yield6666.67%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$1028095347812062.00M$178.9K
Annual income after 10y$998,628,545,336,266,700,000.00$80,797.29
Total dividends collected$1026118102492338.88M$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: ORPHY vs ADC ($10,000, DRIP)

YearORPHY PortfolioORPHY Income/yrADC PortfolioADC Income/yrGap
1← crossover$677,367$666,666.67$10,990$580.36+$666.4KORPHY
2$42,928,313$42,203,530.63$12,301$860.26+$42.92MORPHY
3$2,545,616,701$2,499,683,405.64$14,104$1,298.62+$2545.60MORPHY
4$141,255,910,403$138,532,100,533.89$16,691$2,008.16+$141255.89MORPHY
5$7,335,374,338,812$7,184,230,514,680.15$20,580$3,205.09+$7335374.32MORPHY
6$356,516,885,536,661$348,668,034,994,132.70$26,754$5,330.02+$356516885.51MORPHY
7$16,218,956,689,966,618$15,837,483,622,442,392.00$37,196$9,345.14+$16218956689.93MORPHY
8$690,711,023,145,868,900$673,356,739,487,604,600.00$56,244$17,523.09+$690711023145.81MORPHY
9$27,539,067,734,387,980,000$26,800,006,939,621,900,000.00$94,286$35,736.21+$27539067734387.88MORPHY
10$1,028,095,347,812,062,000,000$998,628,545,336,266,700,000.00$178,949$80,797.29+$1028095347812061.75MORPHY

ORPHY vs ADC: Complete Analysis 2026

ORPHYStock

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cell protective properties of the heat shock response, which protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Its lead candidate is the Arimoclomol, which is in clinical development for diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Full ORPHY Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this ORPHY vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORPHY vs SCHDORPHY vs JEPIORPHY vs OORPHY vs KOORPHY vs MAINORPHY vs NNNORPHY vs EPRTORPHY vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.